{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:09:45Z","timestamp":1791180585721,"version":"4.1.0"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>RANKL is an essential mediator of bone resorption, and its activity is inhibited by osteoprotegerin (OPG). Transgenic (Tg) rats were engineered to continuously overexpress OPG to study the effects of continuous long-term RANKL inhibition on bone volume, density, and strength. Lumbar vertebrae, femurs, and blood were obtained from 1-yr-old female OPG-Tg rats (n = 32) and from age-matched wildtype (WT) controls (n = 23). OPG-Tg rats had significantly greater serum OPG (up to 260-fold) and significantly lower serum TRACP5b and osteocalcin compared with WT controls. Vertebral histomorphometry showed significant reductions in osteoclasts and bone turnover parameters in OPG-Tg rats versus WT controls, and these reductions were associated with significantly greater peak load in vertebrae tested through compression. No apparent differences in bone material properties were observed in OPG-Tg rat vertebrae, based on their unchanged intrinsic strength parameters and their normal linear relationship between vertebral bone mass and strength. Femurs from OPG-Tg rats were of normal length but showed mild osteopetrotic changes, including reduced periosteal perimeter (\u22126%) and an associated reduction in bending strength. Serum OPG levels in WT rats showed no correlations with any measured parameter of bone turnover, mass, or strength, whereas the supraphysiological serum OPG levels in OPG-Tg rats correlated negatively with bone turnover parameters and positively with vertebral bone mass and strength parameters. In summary, low bone turnover after 1 yr of OPG overexpression in rats was associated with increased vertebral bone mass and proportional increases in bone strength, with no evidence for deleterious effects on vertebral material properties.<\/jats:p>","DOI":"10.1359\/jbmr.090215","type":"journal-article","created":{"date-parts":[[2009,3,3]],"date-time":"2009-03-03T19:19:39Z","timestamp":1236107979000},"page":"1234-1246","source":"Crossref","is-referenced-by-count":37,"title":["One Year of Transgenic Overexpression of Osteoprotegerin in Rats Suppressed Bone Resorption and Increased Vertebral Bone Volume, Density, and Strength"],"prefix":"10.1093","volume":"24","author":[{"given":"Michael S","family":"Ominsky","sequence":"first","affiliation":[{"name":"Metabolic Disorders, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Stolina","sequence":"additional","affiliation":[{"name":"Metabolic Disorders, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Li","sequence":"additional","affiliation":[{"name":"Metabolic Disorders, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J","family":"Corbin","sequence":"additional","affiliation":[{"name":"Metabolic Disorders, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franklin J","family":"Asuncion","sequence":"additional","affiliation":[{"name":"Metabolic Disorders, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Barrero","sequence":"additional","affiliation":[{"name":"Metabolic Disorders, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Tian","family":"Niu","sequence":"additional","affiliation":[{"name":"Metabolic Disorders, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Dwyer","sequence":"additional","affiliation":[{"name":"Metabolic Disorders, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Adamu","sequence":"additional","affiliation":[{"name":"Metabolic Disorders, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly S","family":"Warmington","sequence":"additional","affiliation":[{"name":"Metabolic Disorders, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Grisanti","sequence":"additional","affiliation":[{"name":"Metabolic Disorders, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong L","family":"Tan","sequence":"additional","affiliation":[{"name":"Metabolic Disorders, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua Z","family":"Ke","sequence":"additional","affiliation":[{"name":"Metabolic Disorders, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S","family":"Simonet","sequence":"additional","affiliation":[{"name":"Metabolic Disorders, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J","family":"Kostenuik","sequence":"additional","affiliation":[{"name":"Metabolic Disorders, Amgen, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024020319593121900_bib1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1210\/er.2007-0014","article-title":"OPG and RANKL regulation of bone remodeling in health and disease","volume":"29","author":"Kearns","year":"2008","journal-title":"Endocr Rev"},{"key":"2024020319593121900_bib2","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1101\/gad.13.18.2412","article-title":"RANK is essential for osteoclast and lymph node development","volume":"13","author":"Dougall","year":"1999","journal-title":"Genes Dev"},{"key":"2024020319593121900_bib3","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1073\/pnas.97.4.1566","article-title":"RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis, and regulation of bone mass and calcium metabolism","volume":"97","author":"Li","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024020319593121900_bib4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"2024020319593121900_bib5","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1006\/bbrc.1998.8697","article-title":"Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor\/osteoprotegerin","volume":"247","author":"Mizuno","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"2024020319593121900_bib6","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","article-title":"Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification","volume":"12","author":"Bucay","year":"1998","journal-title":"Genes Dev"},{"key":"2024020319593121900_bib7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s007740200049","article-title":"Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis","volume":"20","author":"Mizuno","year":"2002","journal-title":"J Bone Miner Metab"},{"key":"2024020319593121900_bib8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: A novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"2024020319593121900_bib9","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1023\/A:1011229324412","article-title":"The effects of osteoprotegerin on the mechanical properties of rat bone","volume":"12","author":"Ross","year":"2001","journal-title":"J Mater Sci Mater Med"},{"key":"2024020319593121900_bib10","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1210\/endo.142.10.8437","article-title":"OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats","volume":"142","author":"Kostenuik","year":"2001","journal-title":"Endocrinology"},{"key":"2024020319593121900_bib11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1359\/jbmr.060915","article-title":"Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice","volume":"22","author":"Samadfam","year":"2007","journal-title":"J Bone Miner Res"},{"key":"2024020319593121900_bib12","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s00223-004-0028-x","article-title":"Osteoclastogenesis inhibitor factor\/osteoprotegerin reduced bone loss induced by mechanical unloading","volume":"75","author":"Ichinose","year":"2004","journal-title":"Calcif Tissue Int"},{"key":"2024020319593121900_bib13","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1210\/jc.2005-0794","article-title":"REVIEW: Circulating osteoprotegerin ligand and receptor activator for nuclear factor \u03baB ligand: Clinical utility in metabolic bone disease assessment","volume":"90","author":"Rogers","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020319593121900_bib14","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.coph.2005.06.005","article-title":"Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength","volume":"5","author":"Kostenuik","year":"2005","journal-title":"Curr Opin Pharmacol"},{"key":"2024020319593121900_bib15","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1359\/JBMR.050601","article-title":"RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis","volume":"20","author":"Stolina","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2024020319593121900_bib16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1109\/TSMC.1979.4310076","article-title":"A threshold selection method from gray-level histograms","volume":"9","author":"Otsu","year":"1979","journal-title":"IEEE Trans Syst Man Cybern"},{"key":"2024020319593121900_bib17","doi-asserted-by":"crossref","first-page":"7497","DOI":"10.4049\/jimmunol.179.11.7497","article-title":"ContinuousRANKL inhibition in OPG transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses","volume":"179","author":"Stolina","year":"2007","journal-title":"J Immunol"},{"key":"2024020319593121900_bib18","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1210\/en.2004-1583","article-title":"The RANKL inhibitor osteoprotegerin (OPG) causes greater suppression of bone resorption and hypercalcemia compared to bisphosphonates in two models of humoral hypercalcemia of malignancy","volume":"146","author":"Morony","year":"2005","journal-title":"Endocrinology"},{"key":"2024020319593121900_bib19","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"key":"2024020319593121900_bib20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: A randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"J Bone Miner Res"},{"key":"2024020319593121900_bib21","first-page":"S34","article-title":"Serum OPG levels are correlated positively with bone strength and inversely with bone turnover in mature OPG transgenic rats","volume":"78","author":"Ominsky","year":"2006","journal-title":"Calcif Tissue Int"},{"key":"2024020319593121900_bib22","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jcem.87.4.8415","article-title":"Changes in bone density and turnover explain the reduction in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents","volume":"87","author":"Hochberg","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020319593121900_bib23","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S8756-3282(02)00819-0","article-title":"Age and distance from the surface but not menopause reduce osteocyte density in human cancellous bone","volume":"31","author":"Qiu","year":"2002","journal-title":"Bone"},{"key":"2024020319593121900_bib24","doi-asserted-by":"crossref","first-page":"138","DOI":"10.2106\/00004623-196042010-00011","article-title":"In vivo osteocyte death","volume":"42","author":"Frost","year":"1960","journal-title":"J Bone Joint Surg Am"},{"key":"2024020319593121900_bib25","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.jbiomech.2008.01.017","article-title":"Quantitative associations between osteocyte density and biomechanics, microcrack and microstructure in OVX rats vertebral trabeculae","volume":"41","author":"Ma","year":"2008","journal-title":"J Biomech"},{"key":"2024020319593121900_bib26","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1359\/jbmr.080109","article-title":"RANKL inhibition with osteoprotegerin (OPG) increases bone strength by improving cortical and trabecular bone achitecture in ovariectomized rats","volume":"23","author":"Ominsky","year":"2008","journal-title":"J Bone Miner Res"},{"key":"2024020319593121900_bib27","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S8756-3282(03)00090-5","article-title":"Serum levels of osteoprotegerin increase with age in a healthy adult population","volume":"32","author":"Kudlacek","year":"2003","journal-title":"Bone"},{"key":"2024020319593121900_bib28","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1359\/jbmr.071114","article-title":"Differential bone metabolism between postmenopausal women with osteoarthritis and osteoporosis","volume":"23","author":"Jiang","year":"2008","journal-title":"J Bone Miner Res"},{"key":"2024020319593121900_bib29","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.bone.2004.12.015","article-title":"Circulating amounts of osteoprotegerin and RANK ligand: Genetic influence and relationship with BMD assessed in female twins","volume":"36","author":"Abrahamsen","year":"2005","journal-title":"Bone"},{"key":"2024020319593121900_bib30","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.bone.2006.06.022","article-title":"No associations between OPG gene polymorphisms or serum levels and measures of osteoporosis in elderly Australian women","volume":"40","author":"Ueland","year":"2007","journal-title":"Bone"},{"key":"2024020319593121900_bib31","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1359\/jbmr.2003.18.5.852","article-title":"Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): A pharmacodynamic and pharmacokinetic analysis in rats","volume":"18","author":"Capparelli","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024020319593121900_bib32","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/(SICI)1097-4644(19990201)72:2<251::AID-JCB9>3.0.CO;2-W","article-title":"Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors","volume":"72","author":"Shalhoub","year":"1999","journal-title":"J Cell Biochem"},{"key":"2024020319593121900_bib33","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1126\/science.180.4088.875","article-title":"Osteopetrosis cured by temporary parabiosis","volume":"180","author":"Walker","year":"1973","journal-title":"Science"},{"key":"2024020319593121900_bib34","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1359\/jbmr.2001.16.8.1416","article-title":"Expression profiles of receptor activator of nuclear factor \u03baB ligand, receptor activator of nuclear factor \u03baB, and osteoprotegerin messenger mRAN in aged ovariectomized rat bones","volume":"16","author":"Ikeda","year":"2001","journal-title":"J Bone Miner Res"},{"key":"2024020319593121900_bib35","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1210\/endo.141.9.7634","article-title":"Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function","volume":"141","author":"Udagawa","year":"2000","journal-title":"Endocrinology"},{"key":"2024020319593121900_bib36","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1177\/002215540205000708","article-title":"Localization of osteoprotegerin (OPG) on bone surfaces and cement lines in rat tibia","volume":"50","author":"Nakamura","year":"2002","journal-title":"J Histochem Cytochem"},{"key":"2024020319593121900_bib37","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.bone.2006.05.024","article-title":"Dried plum prevents bone loss in a male osteoporosis model via IGF-I and the RANK pathway","volume":"39","author":"Franklin","year":"2006","journal-title":"Bone"},{"key":"2024020319593121900_bib38","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10735-007-9158-6","article-title":"OPG and RANKL mRNA and protein expressions in the primary and secondary metaphyseal trabecular bone of PTH-treated rats are independent of that of SOST","volume":"39","author":"Silvestrini","year":"2008","journal-title":"J Mol Histol"},{"key":"2024020319593121900_bib39","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1902\/jop.2007.070073","article-title":"RANKL inhibition via osteoprotegerin blocks bone loss in experimental periodontitis","volume":"78","author":"Jin","year":"2007","journal-title":"J Periodontol"},{"key":"2024020319593121900_bib40","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1359\/jbmr.060905","article-title":"RANKL inhibition: A novel strategy to decrease femoral head deformity after ischemic necrosis","volume":"21","author":"Kim","year":"2006","journal-title":"J Bone Miner Res"},{"key":"2024020319593121900_bib41","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1006\/bbrc.1998.8443","article-title":"Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor","volume":"245","author":"Tomoyasu","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"2024020319593121900_bib42","author":"Stolina","year":"2008"},{"key":"2024020319593121900_bib43","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/jbmr.5650081113","article-title":"Interrelationships between densitometric, geometric and mechanical properties of rat femora: Inferences concerning mechanical regulation of bone modeling","volume":"8","author":"Ferretti","year":"1993","journal-title":"J Bone Miner Res"},{"key":"2024020319593121900_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ar.1092190104","article-title":"Bone \u201cmass\u201d and the \u201cmechanostat\u201d: A proposal","volume":"219","author":"Frost","year":"1987","journal-title":"Anat Rec"},{"key":"2024020319593121900_bib45","first-page":"398","volume-title":"Primer on the Metabolic Bone Disease and Disorders of Mineral Metabolism","author":"Whyte","year":"2006","edition":"6th ed"},{"key":"2024020319593121900_bib46","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.bone.2005.02.016","article-title":"Quantification of metaphyseal modeling in children treated with bisphosphonates","volume":"36","author":"Ward","year":"2005","journal-title":"Bone"},{"key":"2024020319593121900_bib47","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0021-9290(01)00203-2","article-title":"Mechanical properties in long bones of rat osteopetrotic mutations","volume":"35","author":"Jamsa","year":"2002","journal-title":"J Biomech"},{"key":"2024020319593121900_bib48","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1359\/jbmr.2000.15.10.1905","article-title":"Mineral density and bone strength are dissociated in long bones of rat osteopetrotic mutations","volume":"25","author":"Tuukkanen","year":"2000","journal-title":"J Bone Miner Res"},{"key":"2024020319593121900_bib49","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1359\/JBMR.041232","article-title":"Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study","volume":"20","author":"Gatti","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2024020319593121900_bib50","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/ncpendmet0075","article-title":"Should children with osteogenesis imperfecta be treated with bisphosphonates","volume":"2","author":"Marini","year":"2006","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"2024020319593121900_bib51","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJMoa023110","article-title":"Bisphosphonate-induced osteopetrosis","volume":"349","author":"Whyte","year":"2003","journal-title":"N Engl J Med"},{"key":"2024020319593121900_bib52","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S8756-3282(00)00256-8","article-title":"Osteoprotegerin mitigates tail suspension-induced osteopenia","volume":"26","author":"Bateman","year":"2000","journal-title":"Bone"},{"key":"2024020319593121900_bib53","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00198-007-0363-7","article-title":"The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in intact cynomolgus monkeys","volume":"18","author":"Ominsky","year":"2007","journal-title":"Osteoporos Int"},{"key":"2024020319593121900_bib54","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF01320915","article-title":"Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties","volume":"53","author":"Guy","year":"1993","journal-title":"Calcif Tissue Int"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.090215","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/24\/7\/1234\/56574185\/5650240712.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/24\/7\/1234\/56574185\/5650240712.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:52:16Z","timestamp":1710341536000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/24\/7\/1234-1246\/7599798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,1]]},"references-count":54,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2009,7,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.090215","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2009,7,1]]},"published":{"date-parts":[[2009,7,1]]}}}